Immunotherapy for Prostate Cancer: Where We Are Headed.

about

Recent Advances in Prostate Cancer Treatment and Drug Discovery.Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

P2860

Q54111821-5B8ECDCB-C724-4E99-81B5-FA868E3AB7C3 Q57108205-B567F2B6-6971-46F5-80FE-BAB80C119B3C Q58698705-EDDE96ED-EC6C-4EA4-810F-35F853F6528C

P2860

Immunotherapy for Prostate Cancer: Where We Are Headed.

Item

http://www.wikidata.org/entity/Q48176349

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Immunotherapy for Prostate Cancer: Where We Are Headed.

@en

Immunotherapy for Prostate Cancer: Where We Are Headed.

@nl

type

Item

label

Immunotherapy for Prostate Cancer: Where We Are Headed.

@en

Immunotherapy for Prostate Cancer: Where We Are Headed.

@nl

prefLabel

Immunotherapy for Prostate Cancer: Where We Are Headed.

@en

Immunotherapy for Prostate Cancer: Where We Are Headed.

@nl

P1476

Immunotherapy for Prostate Cancer: Where We Are Headed.

@en

P2093

Alberto Farolfi

http://www.w3.org/2001/XMLSchema#string

Cecilia Menna

http://www.w3.org/2001/XMLSchema#string

Delia De Lisi

http://www.w3.org/2001/XMLSchema#string

Domenico Barone

http://www.w3.org/2001/XMLSchema#string

Filippo Martignano

http://www.w3.org/2001/XMLSchema#string

Giorgia Ravaglia

http://www.w3.org/2001/XMLSchema#string

Lorena Rossi

http://www.w3.org/2001/XMLSchema#string

Roberta Gunelli

http://www.w3.org/2001/XMLSchema#string

Salvatore Roberto Bellia

http://www.w3.org/2001/XMLSchema#string

Ugo De Giorgi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

Integrative clinical genomics of advanced prostate cancer.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

P31

scholarly article

review article

P356

10.3390/IJMS18122627

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vincenza Conteduca

Giuseppe Schepisi

P5008

ScienceSource

P577

2017-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29206214

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

prostate cancer

P932

5751230

http://www.w3.org/2001/XMLSchema#string

Immunotherapy for Prostate Cancer: Where We Are Headed.

about

P2860

P2860

Immunotherapy for Prostate Cancer: Where We Are Headed.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932